Clinical trials: Adaptive Immunity
Prevention of COVID-19
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2.
- Trial name
- EU-COVAT-1 (NCT05160766)
- Testing
- Comirnaty (BTN162b2), Spikevax (mRNA-1273)
- Where
- 9 sites in Germany, Lithuania and 2 more
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Oliver Cornely, MD
Influenza
Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)
The purpose of this study is provide a better understanding of the adaptive immune response to the licensed flu vaccines. The investigators hope the information learned from this study will help identify and describe important…
- Trial name
- NCT03028987
- Testing
- Fluzone®, FluMist®
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stanford University
Innate Inflammatory Response, Vaccination
PFAS Exposure and Immune Response to Vaccination in Adults
This clinical trial aims to investigate how exposure to Perfluorononanoic acid (PFNA), a type of per- and polyfluoroalkyl substance (PFAS), affects the immune response to the standard tetanus and diphtheria (Td) vaccine.
- Conditions
- Innate Inflammatory Response, Vaccination, Diphtheria, Tetanus
- Trial name
- NCT06588530
- Testing
- TENIVAC
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Common Cold
Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)
The study is designed to assess the effect of ingestion of a probiotic on innate and adaptive host responses to rhinovirus infection.
- Trial name
- EPIARR (NCT01669603)
- Testing
- Bifidobacterium lactis Bl-04, Rhinovirus
- Where
- United States
- Volunteers
- 789 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Influenza
Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly
Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular.
- Trial name
- NCT01232868
- Testing
- trivalent Influenza vaccine (TIV)
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Emory University
Immunodeficiencies, Immune Dysregulations
COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Background: The immune system defends the body against disease and infection. Immune deficiencies are health conditions that decrease the strength of this response.
- Trial name
- PERSIST (NCT04852276)
- Where
- United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
RSV Infection
The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus
This study will for the first time systematically investigate the immune responses in an elderly cohort challenged with a well-defined RSV inoculum.
- Trial name
- INFLAMMAGE (NCT03728413)
- Testing
- RSV A Memphis 37
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Influenza
The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics
The goal of this study is to understand the impact on the human immune system's response to the four strain flu vaccine in individuals who have "imprinted" on specific influenza strains.
- Trial name
- FLU2 (NCT03686514)
- Testing
- FLUARIX QUADRIVALENT
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Emory University
Hepatitis B
Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System
This study aims to develop innovative immunological read-outs and new technologies in order to further characterise the early immune response and its kinetics as well as the adaptive immune responses to adjuvanted vaccines.
- Trial name
- NCT01777295
- Testing
- Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A., EngerixTM-B
- Where
- Belgium
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
The purpose of the study is to get a better understanding of the natural and adaptive immune response to the flu virus and to compare the immune cell responses to FDA-licensed flu vaccines in nasal mucosal cells and in blood.
- Trial name
- NCT03028974
- Testing
- Fluzone®, FluMist®
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Stanford University